

Steps before prequalification

I. BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier

The company Lupin Limited submitted in 2024 an application for [HA790 trade name]* (HA790) to be assessed with the aim of including [HA790 trade name] in the list of prequalified medicinal products for the treatment of HIV-1 infection.

[HA790 trade name] was assessed according to the ‘*Procedure for Assessing the Acceptability, in Principle, of Pharmaceutical Products for Purchase by United Nations Agencies*’ by the team of WHO assessors. The assessors are senior experts, mainly from national authorities, invited by WHO to participate in the prequalification assessment process.

2. Steps taken in the evaluation of the product

July 2023	The manufacturer one API was inspected for compliance with WHO requirements for GMP.
January 2024	During the meeting of the assessment team the safety and efficacy data were reviewed and further information was requested.
February and April 2024	In between the meetings of the assessment team the quality data were reviewed and further information was requested.
March 2024	The applicant's response letter was received.
March 2024	The safety and efficacy data were reviewed and found to comply with the relevant WHO requirements.
June 2024	The applicant's response letter was received.
June 2024	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
August 2024	The applicant's response letter was received.
September 2024	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
October 2024	A desk review for evaluation of compliance of the manufacturer of the FPP for GMP was conducted and it met WHO requirements.
October 2024	The applicant's response letter was received.
November 2024	During the meeting of the assessment team the additional quality data were reviewed and further information was requested.
January 2025	The sites relevant for the bioequivalence study were inspected for compliance with WHO requirements for GCP.
February 2025	The applicant's response letter was received.
April 2025	The manufacturer of one API was inspected for compliance with WHO requirements for GMP.
March and May 2025	During the meetings of the assessment team the additional quality data were reviewed and further information was requested.
May 2025	The applicant's response letter was received.
June 2025	The additional quality data were reviewed and further information was requested.
June 2025	The applicant's response letter was received.
June 2025	The quality data were reviewed and found to comply with the relevant WHO requirements.
June 2025	A desk review for evaluation of compliance of the manufacturer of one API for GMP was conducted and it met WHO requirements.
June 2025	Product dossier accepted (quality assurance)
05 July 2025	[HA790 trade name] was included in the list of prequalified medicinal products.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

II. GENERAL CONDITIONS FOR THE PREQUALIFICATION

1. Manufacturer and Inspection status

Manufacturer of the finished product and responsible for batch release

Lupin Limited
Plot No. 6A1, 6A2, Sector-17
Special Economic Zone
MIHAN Notified Area
Nagpur
Maharashtra – 441108
India

Inspection status

Desk review of one of the API sites was found to be in compliance with WHO requirements for GMP.
The sites inspected were found to be in compliance with WHO requirements for GMP, GLP and GCP.

2. (Advice on) Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

Further information is available at:

<https://extranet.who.int/prequal/medicines/prequalified/finished-pharmaceutical-products>